Startups
Oramed Pharmaceuticals (NASDAQ: ORMP)
Oramed has developed an innovative technology to transform injectable treatments into oral therapies.
Oramed’s flagship product, an oral insulin capsule, has the potential to better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles.
Oramed’s oral insulin is currently in advanced clinical trials under the US FDA for both type 1 and type 2 diabetes.
In addition to oral insulin, the company’s proprietary POD™ technology can be used to orally administer a number of protein-based therapies, which are available only via injection.
Nadav Kidron, Esq, CEO, President & Director
Mr. Kidron serves as Chief Executive Officer & Director of Oramed Pharmaceuticals, which he co-founded in 2006.
Mr. Kidron is an entrepreneur whose experience includes senior executive roles in a wide range of industries.
He co-founded Entera Bio as a joint venture formed by Oramed and DNA Biomedical Solutions. He is a member of the IATI Board, and an international lecturer on Israel’s entrepreneurial culture and the country’s roots as an oasis of innovative ideas.
He holds a bachelors degree in law and an international masters in business administration, both from Bar-Ilan University in Israel. Mr. Kidron is a fellow of the Merage Business Executive Leadership Program and a member of the Israeli Bar Association.
Oramed has developed an innovative technology to transform injectable treatments into oral therapies.
Oramed’s flagship product, an oral insulin capsule, has the potential to better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles.
Oramed’s oral insulin is currently in advanced clinical trials under the US FDA for both type 1 and type 2 diabetes.
In addition to oral insulin, the company’s proprietary POD™ technology can be used to orally administer a number of protein-based therapies, which are available only via injection.
Nadav Kidron, Esq, CEO, President & Director
Mr. Kidron serves as Chief Executive Officer & Director of Oramed Pharmaceuticals, which he co-founded in 2006.
Mr. Kidron is an entrepreneur whose experience includes senior executive roles in a wide range of industries.
He co-founded Entera Bio as a joint venture formed by Oramed and DNA Biomedical Solutions. He is a member of the IATI Board, and an international lecturer on Israel’s entrepreneurial culture and the country’s roots as an oasis of innovative ideas.
He holds a bachelors degree in law and an international masters in business administration, both from Bar-Ilan University in Israel. Mr. Kidron is a fellow of the Merage Business Executive Leadership Program and a member of the Israeli Bar Association.
Overview
Location
Israel, Jerusalem District, Jerusalem
Employees
11-50
Founded date
2006
Mentions in press and media 25
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Nov 18, 2022 | MEDICOX Signs Contract with ORAMED to Distribute Oral Insulin in South Korea | - MEDICOX secures distribution right for ORAMED's oral insulin in South Korea after phase 3 of FDA approval - Contract scale up to 18 million dollars for developmental milestone and up to 15% royalty for sales - ORAMED says 1 in 7 Kore... |
| Jan 12, 2022 | Oramed Issues Annual Message to Shareholders | NEW YORK, Jan. 12, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from ... |
| Jan 12, 2022 | Oramed Issues Annual Message to Shareholders | NEW YORK, Jan. 12, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from ... |
| Dec 29, 2021 | Oramed Subsidiary Oravax Medical Signs Cooperation and Purchase Agreement for an Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccines with Tan Thanh Holdings to Commercialize in Southeast Asia | NEW YORK, Dec. 29, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that its s... |
| Dec 29, 2021 | Oramed Subsidiary Oravax Medical Signs Cooperation and Purchase Agreement for an Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccines with Tan Thanh Holdings to Commercialize in Southeast Asia | Initial pre-purchase of 10 million doses of oral vaccines with a potential deal for further orders worth hundreds of millions of dollars Prospective patient population of approximately 660 million throughout the Association of Southeast Asi... |
| Dec 29, 2021 | Oramed Subsidiary Oravax Medical Signs Cooperation and Purchase Agreement for an Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccines with Tan Thanh Holdings to Commercialize in Southeast Asia | NEW YORK, Dec. 29, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that its s... |
| Dec 14, 2021 | Oramed Subsidiary Oravax Announces First Participant Enrolled in Phase 1 Oral COVID-19 Vaccine Trial in South Africa | NEW YORK, Dec. 14, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced today that its s... |
| Nov 24, 2021 | Oramed to Join MSCI USA Small Cap Index | NEW YORK, Nov. 24, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced today that its c... |
| Nov 24, 2021 | Oramed to Join MSCI USA Small Cap Index | NEW YORK, Nov. 24, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced today that its c... |
Show more
Reviews 0
FAQ about Oramed Pharma
When was Oramed Pharma founded?
Oramed Pharma was founded in 2006.
What has the press written about Oramed Pharma?
Parsers VC has collected 25 articles mentioning Oramed Pharma, among them “MEDICOX Signs Contract with ORAMED to Distribute Oral Insulin in South Korea” (Nov 18, 2022) and “Oramed Issues Annual Message to Shareholders” (Jan 12, 2022).
Is Oramed Pharma still active?
Yes, Oramed Pharma is active; its latest activity on Parsers VC dates from Jan 14, 2026.